Cannabis Edibles for Huntington's Disease: Three Trials, Three Molecules, No Change

Three controlled trials have tested a cannabinoid in Huntington's disease, and each picked a different molecule. An Arizona group gave CBD in 1991. A Birmingham group gave nabilone, a synthetic THC relative, in 2009. A Madrid group gave Sativex, the THC and CBD mouth spray, in 2016. Together they enrolled 85 people, and none of them changed the course of the disease. One produced a small, short signal on chorea, the involuntary movement that defines HD for most families.

Our position, stated plainly: cannabis has no place as a Huntington's treatment, and THC deserves more caution here than almost anywhere else on this site. Huntington's brings high rates of depression and suicidal thinking, every approved chorea drug carries a boxed warning for exactly that, and THC's effects on mood are the least predictable thing about it. Anyone already using cannabis for sleep or appetite should make sure the HD clinic team knows.

Does cannabis help Huntington's disease?

Barely, and only in one of three trials. CBD did no better than placebo for chorea in 1991. Sativex did no better than placebo on motor, thinking, behaviour or function scores in 2016. Nabilone improved the chorea score by 1.68 points in a five-week pilot. The National Academies called the evidence insufficient to support or refute benefit.

All three were crossovers, so every patient took both drug and placebo in turn. The National Academies report of 2017 reviewed the first two and wrote Conclusion 4-10: insufficient evidence to support or refute the conclusion that oral cannabinoids treat chorea and certain neuropsychiatric symptoms of Huntington's. It added that cannabis itself had never been studied in the disease. The Sativex trial came out the year before the report and was not part of its review, and its null result adds nothing on the positive side. A 2022 systematic review of movement-disorder trials reached the same count: of the three Huntington's trials, only the nabilone one found symptom relief.

What did the nabilone trial actually show?

A small chorea benefit that did not reach the main outcome. In the Birmingham pilot, 44 patients took nabilone at 1 or 2mg daily and placebo for five weeks each. The primary measure, total motor score, moved 0.86 points with a confidence interval crossing zero. Chorea improved by 1.68 points, and a neuropsychiatric inventory improved by 6.43.

The authors reported no psychotic episodes and called the drug safe and well tolerated, and asked for a larger, longer trial. Seventeen years later, the indexed literature holds no such trial. The National Academies noted that only 37 patients were evaluable and that the wide confidence intervals lowered the weight of the result.

The American Academy of Neurology's 2012 chorea guideline, by Armstrong and Miyasaki, used this trial to give nabilone a Level C recommendation: clinicians can prescribe it for modest decreases in chorea, defined as 1 to under 2 points on the chorea score. In the same sentence it rated the evidence insufficient for long-term use, citing abuse potential. Its Level B options were tetrabenazine, amantadine and riluzole. PubMed now lists that guideline as retired.

For scale, consider what came next. In KINECT-HD, a 2023 phase 3 trial of valbenazine with 125 patients in the analysis, chorea scores fell 4.6 points on the drug and 1.4 on placebo, a 3.2-point difference, over 12 weeks. That is roughly twice the nabilone pilot's effect, in a trial nearly three times the size, and it is the kind of evidence behind valbenazine's FDA indication for Huntington's chorea. Nabilone has no such indication.

Does CBD help Huntington's chorea?

Not at the dose tested, which was enormous. Consroe's 1991 trial gave 15 patients who were off antipsychotics about 700mg of CBD a day for six weeks. CBD did no better than placebo on chorea or any other measure, and it caused no toxicity either. The authors' summary: neither symptomatically effective nor toxic.

Seven hundred milligrams a day is 28 of the 25mg CBD gummies that fill the wellness aisle, every day, for six weeks, and it moved nothing. A tin of low-dose CBD mints sold with a neuroprotection story is working from a smaller dose than a trial that already failed.

The Madrid Sativex trial deserves its own sentence because it was the most careful of the three. Its primary aim was safety, and on that it passed: no serious adverse events and no clinical worsening over 12 weeks. It also measured blood biomarkers to look for any sign of the neuroprotection seen in mouse models, and found no significant molecular change. The authors suggested future trials try higher doses, longer treatment or other cannabinoid combinations.

The most encouraging Huntington's paper is uncontrolled. In 2018 a Bochum group led by Saft described seven patients with early-onset disease whose dystonia (sustained, twisting muscle contractions) improved after starting cannabinoids, with the dystonia subscore falling from 12.3 to 8.0 and some patients gaining weight. Seven patients, no placebo arm, and a subgroup most HD families do not belong to.

Why does THC's effect on mood matter more in Huntington's?

Because the disease already carries a high suicide risk. A Dutch study found suicidal thinking in 20% of mutation carriers, with or without motor symptoms, against none of 56 non-carriers. The National Academies found moderate evidence associating cannabis use with more suicidal thoughts and attempts, highest in heavier users.

The numbers in Huntington's are stark. In Hubers and colleagues' 2012 Leiden study of 152 carriers, a depressed mood was the strongest predictor of suicidal thinking two years later. Their 2013 European cohort found suicidal thoughts in 8.0% of carriers at baseline, and use of benzodiazepines, another sedating drug class, predicted new suicidal thinking over four years. A 1993 analysis of the US National Huntington's Disease Research Roster found suicide listed as the cause of death for 205 of 2,793 people, or 7.3%, a figure that included at-risk relatives as well as patients.

The National Academies also found moderate evidence of a small increased risk of developing depressive disorders among cannabis users. Those are statistical associations from general populations, and they do not prove that a gummy causes low mood. They do mean the direction of risk points the wrong way in a disease where mood is already the most dangerous symptom. The psychiatric side of THC is covered in more depth on our psychosis risk page.

The chorea drugs make the same point from the other direction. Xenazine (tetrabenazine, approved 2008), Austedo (deutetrabenazine, approved 2017) and Ingrezza (valbenazine, approved for Huntington's chorea on August 18, 2023) all carry a boxed warning that they can increase depression and suicidal thoughts and behaviour in Huntington's. The tetrabenazine and deutetrabenazine labels list suicidal patients (actively suicidal, in Xenazine's wording) and untreated or inadequately treated depression as contraindications. In the tetrabenazine trial, 10 of 54 patients (19%) reported depression or worsening depression against none of 30 on placebo. In Ingrezza's open-label extension, 9 of 125 patients reported suicidal thoughts and 3 attempted suicide.

If mood drops, or thoughts of suicide appear, that is urgent. Contact the HD clinic or prescribing neurologist the same day. In the US, call or text 988 to reach the 988 Suicide and Crisis Lifeline, which is free, confidential and open 24 hours a day, or call emergency services.

Can cannabis help weight loss in Huntington's?

No trial has tested it. Unintended weight loss is a hallmark of Huntington's: across 517 early-stage European patients, body mass index fell 0.15 units a year, faster in people with longer CAG repeats. The authors traced it to a hypermetabolic state, which puts the problem on the burning side of the ledger, and THC works on the eating side.

That study found no link between the rate of weight loss and motor, cognitive or behavioural scores, and in the matching mouse model the animals with longer repeats ate more and still weighed less. Weight matters for the course of the disease, too. Among 5,821 carriers in the Enroll-HD study, a higher starting body mass index went with slower functional, motor and cognitive decline.

So the appetite question is a fair one. The THC answer is thin: in older adults with poor appetite (no Huntington's trial exists), the best-designed trial found almost no extra eating, as our appetite loss page explains. An HD dietitian working on calorie density will move the scale further than a gummy.

Is a gummy safe if swallowing has changed?

That is a question for a speech and language therapist. Swallowing trouble starts early in Huntington's and worsens with each stage: in a 2025 San Diego study of 87 gene carriers, almost half of those at the most advanced stage reported severe difficulty. A chewy gummy is a texture the therapist would want to assess first.

The tetrabenazine label notes that dysphagia is part of the disease, that drugs reducing dopamine signalling have been linked to esophageal dysmotility, and that some trial cases of dysphagia came with aspiration pneumonia. The drug makers have adjusted for it: Ingrezza Sprinkle is a capsule meant to be opened over a tablespoon of applesauce, yogurt or pudding. The cannabis shelf offers gelatin squares.

What if I already use cannabis with Huntington's?

Tell the HD clinic team and the prescribing neurologist, and keep taking the chorea medication exactly as prescribed. The tetrabenazine and deutetrabenazine labels warn that alcohol and other sedating drugs add to their sedation, and THC is sedating. Mood changes deserve the closest watching, by the patient and by the family.

The labels ask that caregivers and families be told about the depression risk and report worrying changes to the treating physician, which makes the family part of the monitoring. A family that knows a gummy is in the mix can tell the clinic when the low mood started. Timing matters for that, because an edible's effects arrive 30 minutes to 2 hours after eating and the main effects last 4 to 8 hours, per our edible timing guide. The trial doses here (1 to 2mg of nabilone, up to 12 sprays of Sativex) came with a research team watching every visit, which is the part a dispensary purchase leaves out.